Aims and Scope

Aim of the Journal

The Journal of Hematology and Clinical Research (JHCR) aims to provide a high-quality, open access platform for the rapid, responsible, and ethically sound publication of research dedicated to blood and blood-forming tissues, hematologic diseases, and their clinical management. It reflects the thematic structure, policy ecosystem, and open access posture that are already visible across legacy pages on https://www.hematologyresjournal.com/ (Policies, Open Access, Grievances, Waiver, Repository). By consolidating that scattered information into a single, structured Aims and Scope page, the journal makes it easier for authors, reviewers, and indexers to understand what the journal publishes and why.

JHCR prioritizes manuscripts that can positively influence diagnosis, prognosis, therapeutic decisions, transfusion practices, laboratory standardization, and patient safety in hematology. We welcome contributions that span the translational continuum—from cellular and molecular insights to bedside clinical interventions.

Scope of the Journal

The journal’s scope is intentionally broad to match the real-world overlaps seen in hematology services and to capture diverse article types listed on the legacy site (original articles, case reports, reviews, editorials, special issues).

Core Hematology Domains

Malignant hematology: acute and chronic leukemias, lymphomas, multiple myeloma, plasma cell dyscrasias, myelodysplastic syndromes, myeloproliferative neoplasms, and therapy-related neoplasms.
Benign hematology: anemias (nutritional, hemolytic, aplastic), hemoglobinopathies and thalassemias, cytopenias, bone marrow failure syndromes, immune-mediated hematologic disorders.
Thrombosis and hemostasis: bleeding diatheses, inherited and acquired coagulation disorders, thrombophilia, anticoagulation management, HIT, DIC, perioperative hemostatic management.
Transfusion medicine and blood banking: donor screening, blood component therapy, massive transfusion protocols, transfusion reactions, hemovigilance, patient blood management.
Hematopathology and diagnostic hematology: bone marrow and lymph node pathology, flow cytometry, cytogenetics, molecular diagnostics, laboratory standardization and quality control.

In addition to these core areas, JHCR recognizes that modern hematology is deeply interconnected with oncology, immunology, infectious diseases (particularly hemato-infectious complications), transplantation, and cellular therapies. Therefore, the journal encourages submissions that integrate these perspectives.

Clinical and Translational Hematology

Clinical research is central to the journal’s identity and is repeatedly emphasized on the legacy site through its “current issue,” “early online,” and “article preparatory guidelines” sections. JHCR will continue to publish clinical investigations that are:

Prospective or retrospective cohort studies on hematologic malignancies and benign disorders.
Clinical trials and therapeutic evaluations including targeted therapies, monoclonal antibodies, CAR-T, gene therapy for hemoglobin disorders, growth factors, and novel anticoagulants.
Outcomes and survivorship studies capturing real-world data in hematology clinics, transplant units, and day-care chemotherapy services.
Health services and implementation research on laboratory turnaround times, transfusion utilization, and safety indicators.

Submissions that bring LMIC-focused hematology perspectives—anemia of chronic infection, pediatric hemoglobinopathies, transfusion constraints, or infection-related marrow suppression—are highly encouraged, aligning with the waiver approach visible on the legacy waiver page.

Laboratory Hematology, Diagnostics, and Standardization

Given that the legacy JHCR site already exposes its Repository, Digital Archiving, and Open Access policies—features that presuppose structured and machine-readable article outputs—the updated scope formally welcomes laboratory method papers and diagnostic standards that support harmonization across hematology labs.

Topics include:

Novel approaches to flow cytometric immunophenotyping.
Next-generation sequencing (NGS) panels for myeloid or lymphoid malignancies.
Laboratory algorithms for anemia workup, hemolysis detection, or DIC scoring.
Validation of POCT hematology devices for resource-limited settings.
QA/QC, EQA participation, and laboratory accreditation narratives relevant to hematology.

Such papers are especially useful to readers from diagnostic centers and university hospitals featured in the site’s “university” sub-pages.

Transfusion, Blood Safety, and Cellular Therapies

JHCR uniquely positions transfusion medicine as a major pillar of its scope because many hematology services operate jointly with hospital blood banks. Articles may cover:

Screening algorithms, donor selection, and transfusion-transmitted infection (TTI) surveillance.
RBC, platelet, plasma, cryoprecipitate, and specialized product use in hematologic and obstetric patients.
Apheresis and therapeutic plasma exchange.
Hemovigilance and transfusion reaction case reports.
Collection, processing, and quality control of hematopoietic stem cells.
Cellular therapies, including CAR-T infusion protocols, toxicity management, and supportive care.

This emphasis reflects the journal’s clinical group categorization and open access messaging on the legacy home page.

Global, Community, and Public Health Hematology

Because hematologic disorders such as iron deficiency anemia, thalassemia, sickle cell disease, and malaria-associated anemia place a significant burden on health systems in Africa, the Middle East, South Asia, and Latin America, JHCR will continue to welcome community-level, public health, and health policy manuscripts that:

Measure prevalence, incidence, or mortality related to hematologic disorders in specific populations.
Evaluate screening, early diagnosis, or newborn programs for hemoglobinopathies.
Assess integration of hematology services into national insurance or public health programs.
Provide cost-effectiveness or resource-allocation analysis for hematology interventions.

These topics make the journal particularly attractive to institutions that are already listed on the legacy site’s “university” and “federal university” pages and to authors who may require partial APC waivers.

Accepted Article Formats

Drawing on the journal’s contributor guide, article preparatory guidelines, and policy sub-pages, the following formats are explicitly in scope:

Article Type	Scope Notes for JHCR
Original / Research Articles	Clinical trials, prospective/retrospective cohort studies, registries, translational hematology, large datasets, and multi-center studies.
Reviews / Mini-Reviews	State-of-the-art in malignant hematology, updates on transplant conditioning regimens, targeted therapies, gene therapy, coagulation, and transfusion best practices.
Case Reports / Case Series	Rare or educational hematologic entities, unexpected drug toxicities, atypical transfusion reactions, mixed pathologies.
Short Communications / Brief Reports	Preliminary but important data, technique notes, and negative but well-conducted hematology studies.
Editorials / Commentaries	Invited or editor-submitted viewpoints on practice-changing trials, WHO classification changes, or policy updates.
Special Issue Papers	Managed by guest editors but must follow the journal’s editorial policy, peer review, and ethics statement.

Content Out of Scope

To maintain disciplinary clarity, the following are ordinarily out of scope unless they have a direct and demonstrable hematology linkage:

General internal medicine papers without a hematologic outcome or biomarker.
Purely surgical, orthopedic, or gynecologic studies without perioperative/transfusion hematology relevance.
Case reports on unrelated dermatologic, ENT, or dental pathologies (the legacy platform hosts other HSPI journals for these domains).
Animal-only experimental hematology without translational intent.

Authors unsure about fit are encouraged to consult the editorial office prior to submission.

Alignment with Journal Policies and Indexing

This Aims and Scope page is designed to cohere with the journal’s Open Access Policy, Plagiarism Policy, Peer Review Policy, Repository, Digital Archiving, Withdrawal, and Refund policies already live on the legacy site, thereby providing a single explanatory anchor for indexers and authors.

For indexing services, clearly defined scope is an evaluative criterion; the present document evidences that JHCR is a focused, hematology-first title within the HSPI clinical group, not a generalist clinical journal.

FAQs Related to Aims and Scope

Does JHCR accept pediatric hematology papers?

Yes. Pediatric leukemias, congenital anemias, bleeding disorders, and transfusion issues in neonates and children are within scope.

Can I submit hematology nursing or supportive care research?

Yes, if there is a clear hematology or transfusion focus—e.g., central line care in leukemia patients, transfusion education programs, adherence to anticoagulation in hematology outpatients.

Are meta-analyses and systematic reviews welcome?

Yes. Systematic reviews, scoping reviews, and meta-analyses on hematology topics are encouraged, especially those aligned with PRISMA and hematology society recommendations.

Can I submit qualitative research?

Yes, particularly if it addresses barriers to transfusion services, patient perspectives on lifelong transfusion/chelation, or health-worker practices in hematology clinics.